

Ranica, October 5th, 2021

Titolo: "An Open-Label Phase 2 study to Assess the Effects of C5aR Antagonist Therapy by CCX168 Oral Administration on Ex Vivo Thrombus Formation and Disease Activity in ESRD Patients with Atypical Hemolytic Uremic Syndrome"

Acronimo: ACCESS


EUDRACT N: 2014-004261-24

Sponsor: Istituto di Ricerche Farmacologiche Mario Negri IRCCS

Due to the complexity of the study, the enrollment period was longer than expected, and the investigational drug, CCX168, manufactured by Chemocentryx expired before the completion of enrollment. It was therefore impossible to include additional patients in the study.

In agreement with the company, on February 24, 2017 the study was terminated.

Yours faithfully



Prof. Giuseppe Remuzzi

Sede Legale
Mario Negri Milano

Via Mario Negri, 2 - 20156 Milano
Tel. +39 02 390141
mnegri@marionegri.it

Centro di Ricerche Cliniche
per le Malattie Rare "Aldo e Cele Daccò"
Villa Camozzi

Via G.B. Camozzi, 3 - 24020 Ranica (BG)
Tel. +39 035 45351
villacamozzi@marionegri.it

Centro Anna Maria Astori
Parco Scientifico Tecnologico
Kilometro Rosso

Via Stezzano, 87 - 24126 Bergamo
Tel. +39 035 42131
bergamo@marionegri.it

marionegri.it